BioNTech Results Presentation Deck
Outlook for 2022
1
2
3
4
33
O
Continued COVID-19 vaccine
franchise leadership
Further pipeline
expansion & acceleration
Global footprint &
organization
Corporate Development
Multiple data read-outs expected throughout the year
On track to submit regulatory data package for Omicron-adapted
vaccine pending decision from regulators
Expect data updates for up to 3 additional pipeline programs
Global Development Organization transformation underway to support
pipeline expansion and potential initiation of registration trials
Expanding footprint in Europe, U.S., Asia, and Africal
Investing to expand global mRNA manufacturing capacity with new
production nodes - including deployment of our first BioN Tainer
New partnerships & M&A to accelerate and enable long-term strategy
Extend mRNA platform into new "white spaces" and further expand toolkit
in synthetic biology following collaborations with Medigene and Crescendo
BIONTECHView entire presentation